BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22166235)

  • 1. Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.
    Yee NS; Zhou W; Lee M; Yee RK
    Cancer Lett; 2012 May; 318(1):99-105. PubMed ID: 22166235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
    Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
    Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells.
    Niu W; Liu X; Zhang Z; Xu K; Chen R; Liu E; Wang J; Peng C; Niu J
    Anticancer Res; 2010 Jan; 30(1):135-42. PubMed ID: 20150628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
    Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
    World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
    Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
    Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
    Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
    Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
    Clin Cancer Res; 2005 May; 11(9):3433-8. PubMed ID: 15867245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
    Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E
    J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.
    Park JK; Lee EJ; Esau C; Schmittgen TD
    Pancreas; 2009 Oct; 38(7):e190-9. PubMed ID: 19730150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
    Tan J; Zhou X; Zhu H
    Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
    Kim DJ; Park YS; Kang MG; You YM; Jung Y; Koo H; Kim JA; Kim MJ; Hong SM; Lee KB; Jang JJ; Park KC; Yeom YI
    Exp Cell Res; 2015 Aug; 336(1):119-29. PubMed ID: 26112218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
    Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
    Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
    J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    J Am Coll Surg; 2004 Jun; 198(6):953-9. PubMed ID: 15194078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.
    Liu WS; Yan HJ; Qin RY; Tian R; Wang M; Jiang JX; Shen M; Shi CJ
    Dig Dis Sci; 2009 Jan; 54(1):89-96. PubMed ID: 18594980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
    Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
    Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
    Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
    Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.